Searched for
STRIDES PHARMA LTD POST
Iran war hits India's star investors: Ashish Kacholia, Mukul Agrawal, others see 90% of their stocks lose in 2026Geopolitical tensions stemming from the Iran conflict triggered a broad market sell-off in the March quarter, significantly impacting India...- Strides Pharma Science Q2 Results: Firm posts net profit of Rs 93.66 croreStrides Pharma Science Ltd reported a consolidated net profit of Rs 93.66 crore for the second quarter of FY25, recovering from a Rs 149.45...
- Strides Pharma's OneSource raises Rs 801 crore in pre-listing roundOneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and W...
- OneSource in talks to raise Rs 1,670 crore in pre-listing roundOneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...
- Buy Strides Pharma Science, target price Rs 337: Yes SecuritiesStrides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2854.19 Crore) operating in Pha...
- Strides Pharma Science Q1 results: Drug firm posts net loss of Rs 209 crRevenue from operations of the company stood at Rs 688.36 crore for the quarter under consideration. It was Rs 781.79 crore for the same pe...
- Strides Pharma Q3 results: Net profit declines 62% to Rs 35 crThe company had posted a net profit of Rs 92.33 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a...
- Strides Pharma Science Q1 results: Net profit jumps over 4-fold to Rs 102 crThe company had posted a net profit of Rs 25.36 crore in the corresponding period of the previous fiscal, Strides Pharma Science said in a ...
- Trending stocks: Strides Pharma Science shares rise over 1%A total of 182,073 shares changed hands on the counter till 10:45AM (IST).
- Strides Pharma Q4 results: Posts net loss of Rs 206.57 croreThe company's consolidated revenue from operations stood at Rs 618.64 crore for the quarter under consideration.
- Strides Pharma Science Q3 net declines 69% to Rs 92 croreThe consolidated income of the company increased to Rs 744.66 crore in the Oct-Dec period.
- Strides Pharma Science Q3 profit at Rs 296 croreConsolidated revenue from operations of the company stood at Rs 794.50 crore.
- Strides Pharma drops 3% on USFDA observation for Bengaluru plantThe observations are not material in nature, the company said.
- Strides Pharma Q1 net loss at Rs 4 croreConsolidated revenue from operations stood at Rs 663.46 crore for the quarter under review.
- Strides Shasun gets USFDA nod for generic Ibuprofen capsulesThe generic Ibuprofen capsules, 200 mg, is meant for relieving pain and will be manufactured at the company's oral dosage facility in Banga...
- Strides Shasun Q3 net jumps over 3 fold; plans restructuringThe company had posted a net profit after taxes and minority interest and share of loss of associates and joint ventures of
- Strides Shasun gets CCI nod to buy Sun Pharma's two divisionsStrides Shasun today got CCI's approval to acquire Sun Pharmaceutical's two business divisions in India for Rs 165 crore.
- Sun Pharma looks reasonable post recent correction: Sudip Bandopadhyay"Ranbaxy integration has been a challenge. Things will fall in place. Sun Pharma at current level is good"
- Strides Arcolab Q1 net profit at Rs 32 croreNet sales of the company rose to Rs 161.34 crore for the first quarter, as against Rs 120.42 crore in the same period of last year.
- Strides Q4 net down 10.55 pc at Rs 61.19 crDrug firm Strides Arcolab reported a 10.55 per cent dip in consolidated net profit to Rs 61.19 crore for the fourth quarter ended December ...
Load More
